spacer
 
|

Click below to register.

THURSDAY, 15 JUNE 2017

IFEMA

Feria de Madrid
Avenida del Partenòn
28042 Madrid
Spain

17:30 – 19:00: INTERACTIVE CME ACTIVITY

Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.

This activity is supported by an independent educational grant from Amgen Inc.


OVERVIEW
Biologic agents that revolutionized the treatment of patients with rheumatoid arthritis (RA) are now being reformulated as biosimilar agents. However, many questions remain regarding biosimilars: “What are they?”, “Are they truly interchangeable with their reference biologics?”, and “What are the clinical and financial implications of biosimilars in the treatment of patients with RA?” This live symposium will provide participants with the opportunity to identify key differences between biosimilars and their reference biologics, review policy guidelines for biosimilars including naming and considerations for interchangeability, and assess data on the efficacy, safety, and clinical implications of biosimilars as part of RA patient management.

GOAL
The goal of this activity is to provide rheumatologists and other healthcare professionals with evidence-based insights into the use of biosimilars in the management of patients with RA.

EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants will be better able to do the following:
  • IDENTIFY key differences between biosimilar agents and their reference biologic, including clinical data needed for approval.
  • REVIEW policy guidance on biosimilars, including naming and considerations for interchangeability.
  • ASSESS the most up-to-date evidence on efficacy, safety and clinical implications of biosimilars as part of RA management.
AGENDA
17:30 – 17:40 Overview and Activity Goals
Roy Fleischmann, MD, MACR
17:40 – 18:05 What is a Biosimilar?
Biosimilar Fundamentals and the Regulatory Pathway
Stanley Cohen, MD
18:05 – 18:25 What Data Are Available?
Biosimilars in RA
Professor Jürgen Braun
18:25 – 18:45 What Will Biosimilars Mean?
Clinical and Financial Implications of Biosimilars in RA
Faculty Panel
18:45 – 19:00 Question and Answer Session and Concluding Remarks
Roy Fleischmann, MD, MACR

This schedule is subject to change.

PARTICIPATING FACULTY
Roy Fleischmann, MD, MACR (Chair)
Medical Director
Metroplex Clinical Research Center
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Jürgen Braun
Medical Director
Improvement by Movement GmbH
Berlin, Germany

Stanley Cohen, MD
Medical Director
Metroplex Clinical Research Center
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Co-Director Division of Rheumatology
Dallas, Texas

TARGET AUDIENCE
This live symposium is intended for rheumatologists, internists, primary care providers, nurse practitioners, physician assistants, and other healthcare providers responsible for the diagnosis, treatment and/or management of patients with RA. No prerequisites required.

CME CREDIT (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


An application has been made to the EACCME®.

DISCLOSURE OF CONFLICTS OF INTEREST
The Elsevier Office of Continuing Medical Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Elsevier Office of Continuing Medical Education policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act (ADA)
Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Cathy Zehr at ASiM prior to the live event at czehr@asimcme.com (908-253-9001 ext. 15).

Registration Instructions
Register by clicking arrow below or calling 908-253-9001 ext. 23.

Fee Information
There is no fee for this educational activity.

Submit a case to review at meeting:


<img src="http://www.jhasio1.com/asim/pictures/proceed_pretestASIM.png" alt="procced to pretest" border="0" />


spacer  
  spacer
Advanced Studies in Medicine © 2014 Contact Us
spacer  
spacer